Otonomy Inc

OTIC:NASDAQ
RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 11:18 AM EST
4.07quote price arrow up+0.06 (+1.50%)
Volume
257,287
52 week range
1.53 - 6.98

...

Loading . . .

KEY STATS

  • Open4.09
  • Day High4.20
  • Day Low3.91
  • Prev Close4.01
  • 52 Week High6.98
  • 52 Week High Date01/06/21
  • 52 Week Low1.53
  • 52 Week Low Date03/19/20
  • Market Cap196.30M
  • Shares Out48.23M
  • 10 Day Average Volume0.72M
  • Dividend-
  • Dividend Yield-
  • Beta2.16
  • 1 Year % Change25.46

RATIOS/PROFITABILITY

  • EPS (TTM)-1.33
  • P/E (TTM)-3.06
  • Fwd P/E (NTM)-4.42
  • EBITDA (MRQ)-42.60M
  • ROE (MRQ)-71.59%
  • Revenue (MRQ)0.31M
  • Gross Margin (MRQ)-184.34%
  • Net Margin (MRQ)-14,379.87%
  • Debt To Equity (MRQ)20.17%

EVENTS

  • Earnings Date03/04/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Otonomy Inc News

There is no recent news for this security.

Latest OTIC News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Otonomy, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company's product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial...
Jay Lichter Ph.D.
Chairman
David Weber Ph.D.
President
Paul Cayer
Chief Financial Officer
Robert Savel II
Chief Technology Officer
Address
4796 Executive Dr
San Diego, CA
92121-3090
United States